Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV

References

1. Beeler J. A., van Wyke Coelingh K. 1989; Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63:2941–2950
   [Google Scholar]
2. Chanock R. M., Murphy B. R. 1991; Past efforts to develop safe and effective RSV vaccines. In Animal Models of Respiratory Syncytial Virus Infection pp  35–42 Edited by Meignier B., Murphy B., Ogra P. Lyon: Merieux Foundation;
   [Google Scholar]
3. Crowe J. E. Jr, Bui P. T., Davis A. R., Chanock R. M., Murphy B. R. 1994a; A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:783–790
   [Google Scholar]
4. Crowe J. E. Jr, Bui P. T., London W. T., Davis A. R., Hung P. P., Chanock R. M., Murphy B. R. 1994b; Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12:691–699
   [Google Scholar]
5. Durbin A. P., McAuliffe J. M., Collins P. L., Murphy B. R. 1999; Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 261:319–330
   [Google Scholar]
6. Falsey A. R., Cunningham C. K., Barker W. H., Kouides R. W., Yuen J. B., Menegus M., Weiner L. B., Bonville C. A., Betts R. F. 1995; Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 172:389–394
   [Google Scholar]
7. Hall C. B. 1999; Respiratory syncytial virus: a continuing culprit and conundrum. J Pediatr 135:2–7
   [Google Scholar]
8. Hall C. B. 2001; Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344:1917–1928
   [Google Scholar]
9. Haller A. A., Miller T., Mitiku M., Coelingh K. 2000; Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 74:11626–11635
   [Google Scholar]
10. Haller A. A., MacPhail M., Mitiku M., Tang R. S. 2001; A single amino acid substitution in the viral polymerase creates a temperature-sensitive and attenuated recombinant bovine parainfluenza virus type 3. Virology 288:342–350
    [Google Scholar]
11. Karron R. A., Makhene M., Gay K., Wilson M. H., Clements M. L., Murphy B. R. 1996; Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 15:650–654
    [Google Scholar]
12. Karron R. A., Wright P. F., Crowe J. E. Jr, Clements-Mann M. L., Thompson J., Makhene M., Casey R., Murphy B. R. 1997; Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 176:1428–1436
    [Google Scholar]
13. Martinez I., Dopazo J., Melero J. A. 1997; Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78:2419–2429
    [Google Scholar]
14. Murphy B. R., Hall S. L., Kulkarni A. B., Crowe J. E. Jr, Collins P. L., Connors M., Karron R. A., Chanock R. M. 1994; An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res 32:13–36
    [Google Scholar]
15. Schmidt A. C., McAuliffe J. M., Huang A., Surman S. R., Bailly J. E., Elkins W. R., Collins P. L., Murphy B. R., Skiadopoulos M. H. 2000; Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin–neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74:8922–8929
    [Google Scholar]
16. Schmidt A. C., McAuliffe J. M., Murphy B. R., Collins P. L. 2001; Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 75:4594–4603
    [Google Scholar]
17. Schmidt A. C., Wenzke D. R., McAuliffe J. M., St Claire M., Elkins W. R., Murphy B. R., Collins P. L. 2002; Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 76:1089–1099
    [Google Scholar]
18. Skiadopoulos M. H., Surman S. R., Durbin A. P., Collins P. L., Murphy B. R. 2000; Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes. Virology 272:225–234
    [Google Scholar]